Why Partner

Elevate Your Services To CNS Experts

2025 continued to advance CNS drug delivery, fuelled by innovations in receptor-mediated transport, pressure-driven devices, minimally invasive CSF delivery, and next-generation targeting strategies. Yet, as unmet needs persist, crossing the blood-brain barrier, achieving precise regional targeting, and improving translational predictability, the field faces critical questions: which innovations will truly transform CNS therapeutics, and which will fall short?

After uniting 100+ senior decision-makers including from large pharma, leading biotech, and emerging start-ups, the 7th CNS Drug Delivery Summit returned to provide an unrivalled platform to stay ahead of the latest advances, showcase solutions, and tackle the industry’s most pressing CNS delivery challenges.

In 2026, position your company as the go-to partner for solving the industry’s toughest delivery challenges, from improving translational predictability to enabling minimally invasive local delivery.

Download 2025 Brochure

Experts Need Your Help To:

Overcome limited distribution in the CNS with delivery devices capable of pressure-driven delivery in human-sized brains
Improve visibility into therapeutic targeting with quantitative imaging and microscopy services to model brain distribution after local injection or BBB-crossing
Address the lack of clinically scalable CNS delivery methods with minimally invasive CSF delivery devices
Bridge the translational gap with clinically relevant rodent and animal models for measuring brain delivery and efficient dose escalation studies
Decrease uncertainty in PK/PD outcomes with CRO expertise in pharmacokinetics and pharmacodynamics
Reduce late-stage clinical failures with translatable in vitro blood-brain barrier models with greater ability to recapitulate the BBB

Hear What Our Past Sponsors Have to Say

Small group; friendly discussions. Willingness to share experiences in this very difficult field. Especially loved the speed networking.

CraniUS

The meeting brought together an interesting mix of experts in their field including neuroscientists, pharmacologists, medical engineers, academics, clinicians and business executives, all with the same goal which is to bring therapies to treat CNS diseases. It's unusual to bring such diverse expertise into a room where ideas can be exchanged freely in a relaxed atmosphere.

Neurochase